A human pancreatic adenocarcinoma associated antigen, DU-PAN-2, has recently been partially characterised (Metzgar et al., 1984; Lan et al., 1985) .
Analytical studies performed indicate that DU-PAN-2 epitope is expressed on a mucin-like molecule (Lan et al., 1985; Lan et al., 1987) . However, the exact nature of this antigen is not yet well understood.
As DU-PAN-2 is easily measured in body fluids such as serum, ascites and pancreatic secretions, it has been investigated in different diseases in an attempt to clarify its behaviour and utility as a tumour marker (Metzgar et al., 1984) . The reports available in the literature (Metzgar et al., 1984; Sawabu et al., 1986; Mahvi et al., 1988; Suzuki et al., 1988) demonstrate that a substantial number of patients with pancreatic cancer have high DU-PAN-2 values. However, the specificity of this assay in the differential diagnosis of pancreatic cancer requires further clarification, especially in view of the fact that serum glycoproteic markers may vary in relation to multiple factors, such as disease stage, liver dysfunction and jaundice (Del Favero et al., 1986; Basso et al., 1988a; Fabris et al., 1988) .
The aim of this study was to investigate DU-PAN-2 serum variations in a group of patients with pancreatic cancer, with respect to patients with chronic pancreatitis and other benign and malignant extra-pancreatic digestive diseases. We also ascertained whether DU-PAN-2 variations in the sera of patients with malignant and benign diseases are attributable to liver dysfunction and jaundice.
Materials and methods
The study comprised 104 patients. Thirty-one had pancreatic cancer of duct cell origin (15 males, 16 females, age range 28-79 years) histologically confirmed through the evaluation of intraoperative or autopsy specimens (Cubilla & Fitzgerald, 1978) (5), primary liver cell cancer (6), choledocholithiasis (4), carcinoma of the gallbladder (3), colorectal carcinoma (2), gastric cancer (1), carcinoma of the papilla of Vater (1), chronic hepatitis (1), gallstones (1), cholesterolosis of the gallbladder (1), irritable colon (1).
Serum DU-PAN-2 was assayed by means of an EIA using a commerical kit (Determiner DU-PAN-2, Kyowa Medex Co. Ltd).
Results were stastically evaluated using the analysis of variance and analysis of covariance (Anova and Ancova one way), Bonferroni's test for pairwise comparisons (Wallenstein et al., 1980 ), Student's t-test and receiver-operating characteristic (ROC) curves (Weinstein & Fineberg, 1980 Figure 1 shows the individual values for serum DU-PAN-2 in the groups of patients investigated. The analysis of variance showed a significant difference among groups (F = 11.5, P< 0.001). Patients with pancreatic cancer and extra-pancreatic malignancies had higher mean DU-PAN-2 values than patients with chronic pancreatitis (P<0.005). Patients with pancreatic cancer and liver metastases had a higher DU-PAN-2 mean value than those with non-metastatic cancer (t = 1.89, P < 0.05). Figure 2 illustrates the ROC curves of DU-PAN-2 in distinguishing between pancreatic cancer patients and the other groups.
Significant correlations were found between (1) DU-PAN-2 values on the one hand and (2) total bilirubin (r = 0.299, P<0.01), alkaline-phosphatase (r= 0.522, P<0.001) and ml-' jaundice was present in: 2/3 with chronic pancreatitis, 9/10 with benign and 12/14 with malignant extra-pancreatic diseases. (Metzgar et al., 1984; Sawabu et al., 1986; Mahvi et al., 1988 ); it appears to be lower than that found by us and others for CA 19-9 (Farini et al., 1985; Malesci et al., 1987; Steinberg et al., 1986; Sakamoto et al., 1987; Pleskow et al., 1989 (Suzuki et al., 1988; Haviland et al., 1988) , suggests that this antigen behaves similarly to CA 19-9.
Elsewhere we demonstrated that serum levels of CA 19-9, a mucin type molecule, are greatly affected by liver function alterations (Del Favero et al., 1986; Basso et al., 1988b) 
